The Rosacea Treatment Market is estimated to be valued at US$ 1.91 Bn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Rosacea is a chronic skin condition that causes redness and visible blood vessels on the face. The symptoms commonly associated with rosacea include flushing, blushing, small red pimples, burning/stinging sensation, swelling and red/dilated blood vessels. Various topical formulations such as creams, gels and ointments are used to treat the symptoms of rosacea along with oral medications like antibiotics and immunosuppresants.
Market Dynamics:
Increasing prevalence of rosacea disease across the globe is expected to drive the growth of the market over the forecast period. For instance, according to the Rosacea International organization, the prevalence of rosacea is about 5% but it can be as high as 22% in adults aged 30-50 years. Moreover, increasing awareness regarding rosacea and availability of various treatment options are also fueling the market growth. However, high cost of branded products and side effects associated with medications are some factors that can hinder the market growth. Ongoing research and development activities to develop novel treatment modalities is expected to provide lucrative opportunities for market players during the forecast period. The key market participants are focused on strategic mergers and acquisitions and new product launches to strengthen their market presence.
SWOT Analysis
Strength: Rosacea Treatment market has strong pipeline of drugs in late stage of development which will drive the market growth over the forecast period. Many companies are actively involved is R&D to develop novel treatment options for rosacea. Furthermore, rising awareness about rosacea treatment options among patients is helping people seek medical help.
Weakness: High cost of branded drugs for rosacea can limit their adoption in low and middle income countries. Common side effects of drugs such as dryness, itching and burning sensation leads to poor patient compliance.
Opportunity: Emerging Asian markets with huge patient pool yet to adopt standard treatment practices represents major growth opportunity area for key players. Furthermore, combination therapies can provide new treatment regimens and open new revenue streams.
Threats: Patent expiry of blockbuster drugs will increase generic competition and substantially bring down prices. Rising alternative treatment options such traditional Chinese medicine also poses threat to established pharmacological regimens.
Key Takeaways
The Global Rosacea Treatment Market Trend is expected to witness high growth, exhibiting CAGR of 6.3% over the forecast period, due to increasing prevalence of rosacea globally. As per research estimations, around 5% of worldwide population suffers from some form of rosacea, thereby presenting a huge patient pool targettable for treatment.
Regional analysis: North America currently dominates the global market due to high awareness levels and robust healthcare infrastructure to support diagnosis and management of rosacea. On the other hand, Asia Pacific region is anticipated to grow at fastest pace during the forecast period majorly fueled by expansion of healthcare services in emerging countries like India and China.
Key players operating in the Rosacea Treatment market are Galderma SA, Allergan plc (AbbVie Inc.), Bayer AG, Pfizer Inc., Leo Pharma A/S, Sol-Gel Technologies Ltd., Foamix Pharmaceuticals Ltd., Mayne Pharma, Group Limited, AnaptysBio, Inc., Mylan N.V.
Popular Posts
